journal
Journals Neurotherapeutics : the Journa...

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics

https://read.qxmd.com/read/39242290/extracellular-vesicles-from-mesenchymal-stem-cells-alter-gut-microbiota-and-improve-neuroinflammation-and-motor-impairment-in-rats-with-mild-liver-damage
#1
JOURNAL ARTICLE
Gergana Mincheva, Vicente Felipo, Victoria Moreno-Manzano, Alfonso Benítez-Páez, Marta Llansola
Gut microbiota perturbation and motor dysfunction have been reported in steatosis patients. Rats with mild liver damage (MLD) show motor dysfunction mediated by neuroinflammation and altered GABAergic neurotransmission in the cerebellum. The extracellular vesicles (EV) from mesenchymal stem cells (MSC) have emerged as a promising therapeutic proxy whose molecular basis relies partly upon TGFβ action. This study aimed to assess if MSC-EVs improve motor dysfunction in rats with mild liver damage and analyze underlying mechanisms, including the role of TGFβ, cerebellar neuroinflammation and gut microbiota...
September 5, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39241317/clinical-decision-making-around-commercial-use-of-gene-and-genetic-therapies-for-spinal-muscular-atrophy
#2
REVIEW
Megan A Waldrop
Spinal muscular atrophy is no longer a leading cause of inherited infant death in the United States. Since 2016, three genetic therapies have been approved for the treatment of spinal muscular atrophy. Each therapy has been well studied with robust data for both safety and efficacy. However, there are no head-to-head comparator studies to inform clinical decision making. Thus, treatment selection, timing, and combination therapy is largely up to clinician preference and insurance policies. As the natural history of spinal muscular atrophy continues to change, more data is needed to assist in evidence-based and cost-effective clinical decision making...
September 5, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39237437/life-history-of-a-brain-autoreactive-t-cell-from-thymus-through-intestine-to-blood-brain-barrier-and-brain-lesion
#3
REVIEW
Naoto Kawakami, Hartmut Wekerle
Brain antigen-specific autoreactive T cells seem to play a key role in inducing inflammation in the central nervous system (CNS), a characteristic feature of human multiple sclerosis (MS). These T cells are generated within the thymus, where they escape negative selection and become integrated into the peripheral immune repertoire of immune cells. Typically, these autoreactive T cells rest in the periphery without attacking the CNS. When autoimmune T cells enter gut-associated lymphatic tissue (GALT), they may be stimulated by the microbiota and its metabolites...
September 4, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39232876/a-combination-of-%C3%AE-9-tetrahydrocannabinol-and-cannabidiol-modulates-glutamate-dynamics-in-the-hippocampus-of-an-animal-model-of-alzheimer-s-disease
#4
JOURNAL ARTICLE
Nuria Sánchez-Fernández, Laura Gómez-Acero, Anna Castañé, Albert Adell, Leticia Campa, Jordi Bonaventura, Verónica Brito, Silvia Ginés, Francisco Queiróz, Henrique Silva, João Pedro Lopes, Cátia R Lopes, Marija Radošević, Xavier Gasull, Rodrigo A Cunha, Attila Köfalvi, Samira G Ferreira, Francisco Ciruela, Ester Aso
A combination of Δ9 -tetrahydrocannabinol (Δ9 -THC) and cannabidiol (CBD) at non-psychoactive doses was previously demonstrated to reduce cognitive decline in APP/PS1 mice, an animal model of Alzheimer's disease (AD). However, the neurobiological substrates underlying these therapeutic properties of Δ9 -THC and CBD are not fully understood. Considering that dysregulation of glutamatergic activity contributes to cognitive impairment in AD, the present study evaluates the hypothesis that the combination of these two natural cannabinoids might reverse the alterations in glutamate dynamics within the hippocampus of this animal model of AD...
September 3, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39227284/subcutaneous-efgartigimod-ph20-in-generalized-myasthenia-gravis-a-phase-3-randomized-noninferiority-study-adapt-sc-and-interim-analyses-of-a-long-term-open-label-extension-study-adapt-sc
#5
JOURNAL ARTICLE
James F Howard, Tuan Vu, George Li, Denis Korobko, Marek Smilowski, Li Liu, Fien Gistelinck, Sophie Steeland, Jan Noukens, Benjamin Van Hoorick, Jana Podhorna, Filip Borgions, Yuebing Li, Kimiaki Utsugisawa, Heinz Wiendl, Jan L De Bleecker, Renato Mantegazza
ADAPT-SC (NCT04735432) was designed to evaluate noninferiority of subcutaneous (SC) efgartigimod PH20 to intravenous (IV) efgartigimod in participants with generalized myasthenia gravis (gMG). ADAPT-SC+ (NCT04818671) is an open-label extension study designed to assess long-term safety, tolerability, and efficacy of efgartigimod PH20 SC. Adult participants in ADAPT-SC were randomly assigned to receive a treatment cycle of 4 once-weekly administrations of efgartigimod PH20 SC 1000 ​mg or efgartigimod IV 10 ​mg/kg, followed by 7 weeks of follow-up...
September 2, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39218769/microbiome-and-micronutrient-in-als-from-novel-mechanisms-to-new-treatments
#6
REVIEW
Jun Sun, Yongguo Zhang
Amyotrophic lateral sclerosis is a neurodegenerative disorder. Despite extensive studies, it remains challenging to treat ALS. Recent ALS studies have shown dysbiosis (e.g., loss of microbial diversity and beneficial function in the gut microbiota) is correlated with intestinal inflammation and change of intestinal integrity in ALS. The novel concepts and the roles of microbiome and microbial metabolites through the gut-microbiome-neuron axis in ALS pathogenesis have been slowly recognized by the neurology research field...
August 31, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39214819/corrigendum-to-repetitive-transcranial-magnetic-stimulation-as-a-treatment-for-alzheimer-s-disease-a-randomized-placebo-controlled-double-blind-clinical-trial-neurotherapeutics-21-3-2024-e00331
#7
Zahra Moussavi, Maria Uehara, Grant Rutherford, Brian Lithgow, Colleen Millikin, Xikui Wang, Chandan Saha, Behzad Mansouri, Craig Omelan, Lesley Fellows, Paul B Fitzgerald, Lisa Koski
No abstract text is available yet for this article.
August 30, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39191071/neurosurgical-gene-therapy-for-central-nervous-system-diseases
#8
REVIEW
Ruchit V Patel, Pranav Nanda, R Mark Richardson
Viral vector mediated gene therapies for neurodegenerative and neurodevelopmental conditions that require neurosurgical administration continue to expand. We systematically reviewed the National Institutes of Health (NIH) ClinicalTrials.gov database to identify all clinical trials studying in-vivo viral vector mediated gene therapies targeted to the CNS for neurodegenerative and neurodevelopmental diseases. We isolated studies which delivered therapies using neurosurgical approaches: intracisternal, intraventricular, and/or intraparenchymal...
August 26, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39181859/predictors-of-pharyngeal-electrical-stimulation-treatment-success-in-tracheotomised-stroke-patients-with-dysphagia-secondary-analysis-from-phader-cohort-study
#9
JOURNAL ARTICLE
Ivy Cheng, Philip M Bath, Shaheen Hamdy, Paul Muhle, Satish Mistry, Rainer Dziewas, Sonja Suntrup-Krueger
Pharyngeal electrical stimulation (PES) has emerged as a promising intervention for neurogenic dysphagia, with potential benefits in reducing dysphagia severity in stroke patients. PES may facilitate decannulation in tracheotomised stroke patients with dysphagia, yet the predictive factors for treatment success have not been investigated in detail. This study used data from the PHAryngeal electrical stimulation for treatment of neurogenic Dysphagia European Registry (PHADER) study to identify predictive factors for PES treatment success among patients with post stroke dysphagia who required mechanical ventilation and tracheotomy...
August 23, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39180957/immune-responses-to-central-nervous-system-directed-adeno-associated-virus-gene-therapy-does-direct-cns-delivery-make-a-difference
#10
REVIEW
Ashley L Harkins, Prajakta P Ambegaokar, Allison M Keeler
Adeno-associated virus (AAV) mediated gene therapy is a leading gene delivery platform with potential to transform the landscape of treatment for neurological disorders. While AAV is deemed non-immunogenic compared to other viral vectors, adverse immune reactions have been observed in the clinic, raising concerns. As the central nervous system (CNS) has a tightly regulated immune system, characterized by a degree of tolerance, it has been considered a unique target for AAV gene therapy. AAV vectors have shown promising results for the treatment of several CNS disorders including Spinal Muscular Atrophy, Giant Axonal Neuropathy, Amyotrophic Lateral Sclerosis, Tay Sachs Disease, Parkinson's Disease, and others, demonstrating safety and success...
August 23, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39164165/integrated-elemental-analysis-supports-targeting-copper-perturbations-as-a-therapeutic-strategy-in-multiple-sclerosis
#11
JOURNAL ARTICLE
James B W Hilton, Kai Kysenius, Jeffrey R Liddell, Stephen W Mercer, Carsten Rautengarten, Dominic J Hare, Gojko Buncic, Bence Paul, Simon S Murray, Catriona A McLean, Trevor J Kilpatrick, Joseph S Beckman, Scott Ayton, Ashley I Bush, Anthony R White, Blaine R Roberts, Paul S Donnelly, Peter J Crouch
Multiple sclerosis (MS) is a debilitating affliction of the central nervous system (CNS) that involves demyelination of neuronal axons and neurodegeneration resulting in disability that becomes more pronounced in progressive forms of the disease. The involvement of neurodegeneration in MS underscores the need for effective neuroprotective approaches necessitating identification of new therapeutic targets. Herein, we applied an integrated elemental analysis workflow to human MS-affected spinal cord tissue utilising multiple inductively coupled plasma-mass spectrometry methodologies...
August 19, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39153914/pyrimidine-compounds-by4003-and-by4008-inhibit-glioblastoma-cells-growth-via-modulating-jak3-stat3-signaling-pathway
#12
JOURNAL ARTICLE
Nisar Ahmad, Lixue Chen, Zixi Yuan, Xiaodong Ma, Xiaobo Yang, Yinan Wang, Yongshun Zhao, Huan Jin, Najib Khaidamah, Jinan Wang, Jiashuo Lu, Ziqi Liu, Moli Wu, Qian Wang, Yan Qi, Chong Wang, Yupu Zhao, Yang Piao, Rujie Huang, Yunpeng Diao, Sa Deng, Xiaohong Shu
Glioblastoma (GBM) is a brain tumor characterized by its aggressive and invasive properties. It is found that STAT3 is abnormally activated in GBM, and inhibiting STAT3 signaling can effectively suppress tumor progression. In this study, novel pyrimidine compounds, BY4003 and BY4008, were synthesized to target the JAK3/STAT3 signaling pathway, and their therapeutic efficacy and mechanisms of action were evaluated and compared with Tofacitinib in U251, A172, LN428 and patient-derived glioblastoma cells. The ADP-Glo™ kinase assay was utilized to assessed the inhibitory effects of BY4003 and BY4008 on JAK3, a crucial member of the JAK family...
August 16, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39138027/long-non-coding-rna-snhg12-regulates-leptomeningeal-collateral-remodeling-via-rgma-after-ischemic-stroke
#13
JOURNAL ARTICLE
Anan Jiang, Zijie Wang, Ruiqi Cheng, Shaoru Zhang, Qisi Wu, Xinyue Qin
Leptomeningeal anastomoses or pial collateral arteries are crucial for restoring cerebral blood flow (CBF) after an ischemic stroke. Vascular smooth muscle cells (VSMCs) are hypothesized to regulate the extent of this adaptive response, while the specific molecular mechanisms underlying this process are still being investigated. SNHG12, a long non-coding RNA, has been shown to influence several diseases related angiogenesis, including osteosarcoma and gastric cancer. However, the role of SNHG12 in contractile VSMC dedifferentiation during collateral arteriogenesis-related strokes remains unclear...
August 12, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39129094/association-between-weekend-warrior-physical-activity-and-the-incidence-of-neurodegenerative-diseases
#14
JOURNAL ARTICLE
Yuye Ning, Meilin Chen, Jiaqi An, Manyun Tang, Gary Tse, Jeffrey Shi Kai Chan, Changying Zhao, Yingying Liu, Xinjun Lei, Hua Qiang, Chuan Bai, Hongbing Li, Hang Yu, Yang Yan, Duolao Wang, Guoliang Li
While guidelines recommend 150 ​min of moderate to vigorous physical activity (MVPA) weekly to enhance health, it remains unclear whether concentrating these activities into 1-2 days of the week, "weekend warrior" (WW) pattern, has the same benefit for neurodegenerative diseases (NDDs). This study aimed to evaluate the associations of WW pattern and the risk of NDDs. This prospective study was conducted using accelerometer-based physical activity data for a full week from June 2013 to December 2015 in the UK Biobank...
August 10, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39098392/mendelian-randomization-demonstrates-a-causal-link-between-peripheral-circulating-acylcarnitines-and-intracranial-aneurysms
#15
JOURNAL ARTICLE
Ying Wang, Kang Xie, Junyu Wang, Fenghua Chen, Xi Li, Longbo Zhang
Intracranial aneurysm (IA) is the most prevalent type of cerebral vascular disease causing life-threatening subarachnoid hemorrhages (SAH). A long-term vascular structure remodeling is considered as the main pathophysiological feature of IAs. However, the causal factors triggering the pathophysiological process are not clear. Recently, the abnormalities of peripheral circulating proteins and metabolites have been found in IAs patients and associated with the ruptures. We comprehensively investigated the potential causal relationship between blood metabolites and proteins and IAs using the mendelian randomization (MR) analysis...
August 3, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39096590/stem-cell-therapeutics-and-gene-therapy-for-neurologic-disorders
#16
REVIEW
Kevin S Chen, Emily J Koubek, Stacey A Sakowski, Eva L Feldman
Rapid advances in biological knowledge and technological innovation have greatly advanced the fields of stem cell and gene therapies to combat a broad spectrum of neurologic disorders. Researchers are currently exploring a variety of stem cell types (e.g., embryonic, progenitor, induced pluripotent) and various transplantation strategies, each with its own advantages and drawbacks. Similarly, various gene modification techniques (zinc finger, TALENs, CRISPR-Cas9) are employed with various delivery vectors to modify underlying genetic contributors to neurologic disorders...
August 2, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39054180/the-role-of-the-gut-microbiome-in-the-regulation-of-astrocytes-in-alzheimer-s-disease
#17
REVIEW
Sidhanth Chandra, Robert Vassar
Alzheimer's disease (AD) is the most common neurodegenerative disorder and is the most common cause of dementia. AD is characterized pathologically by proteinaceous aggregates composed of amyloid beta (Aβ) and tau as well as progressive neurodegeneration. Concurrently with the buildup of protein aggregates, a strong neuroinflammatory response, in the form of reactive astrocytosis and microgliosis, occurs in the AD brain. It has recently been shown that the gut microbiome (GMB), composed of trillions of bacteria in the human intestine, can regulate both reactive astrocytosis and microgliosis in the context of both amyloidosis and tauopathy...
July 24, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39054179/role-of-the-gut-microbiome-in-mediating-sex-specific-differences-in-the-pathophysiology-of-alzheimer-s-disease
#18
REVIEW
Piyali Saha, Sangram S Sisodia
Alzheimer's disease (AD) presents distinct pathophysiological features influenced by biological sex, with women disproportionately affected due to sex-specific genetic, hormonal, and epigenetic factors. This review delves into three critical areas of sex differences in AD: First, we explore how genetic predisposition and hormonal changes, particularly those involving sex-specific modifications, influence susceptibility and progression of the disease. Second, we examine the neuroimmune dynamics in AD, emphasizing variations in microglial activity between sexes during crucial developmental stages and the effects of hormonal interventions on disease outcomes...
July 24, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39019729/restoring-consciousness-with-pharmacologic-therapy-mechanisms-targets-and-future-directions
#19
REVIEW
Megan E Barra, Ken Solt, Xin Yu, Brian L Edlow
Severe brain injury impairs consciousness by disrupting a broad spectrum of neurotransmitter systems. Emerging evidence suggests that pharmacologic modulation of specific neurotransmitter systems, such as dopamine, promotes recovery of consciousness. Clinical guidelines now endorse the use of amantadine in individuals with traumatic disorders of consciousness (DoC) based on level 1 evidence, and multiple neurostimulants are used off-label in clinical practice, including methylphenidate, modafinil, bromocriptine, levodopa, and zolpidem...
July 16, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/39004556/ly2940094-an-nopr-antagonist-promotes-oligodendrocyte-generation-and-myelin-recovery-in-an-nopr-independent-manner
#20
JOURNAL ARTICLE
Yanhui Duan, Chenyuan Ye, Jingyi Liao, Xin Xie
The myelin sheath plays crucial roles in brain development and neuronal functions. In the central nervous system, myelin is generated by oligodendrocytes, that differentiate from oligodendrocyte progenitor cells (OPC). In demyelinating diseases, the differentiation capacity of OPC is impaired and remyelination is dampened. Boosting remyelination by promoting OPC differentiation is a novel strategy for the treatment of demyelinating diseases. The opioid system, which consists of four receptors and their ligands, has been implicated in OPC differentiation and myelin formation...
July 13, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
journal
journal
41497
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.